Cargando…

LUHMES Cells: Phenotype Refinement and Development of an MPP(+)-Based Test System for Screening Antiparkinsonian Drugs

The low effectiveness of symptomatic pharmacotherapy for Parkinson’s disease (PD), which compensates for dopamine (DA) deficiency under degeneration of nigrostriatal dopaminergic (DAergic) neurons, could apparently be improved with neuroprotective therapy, which slows down neurodegeneration and PD p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beliakov, Sergei V., Blokhin, Victor, Surkov, Sergey A., Ugrumov, Michael V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821222/ https://www.ncbi.nlm.nih.gov/pubmed/36614176 http://dx.doi.org/10.3390/ijms24010733

Ejemplares similares

A New Method for the Visualization of Living Dopaminergic Neurons and Prospects for Using It to Develop Targeted Drug Delivery to These Cells
por: Blokhin, Victor, et al.
Publicado: (2022)

Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
por: Silva, Sara, et al.
Publicado: (2021)

A STUDY OF PROPHYLACTIC VALUE OF ANTIPARKINSONIAN DRUG
por: Behere, P.B., et al.
Publicado: (1983)

Antipsychotics dosage and antiparkinsonian prescriptions
por: Acquaviva, Eric, et al.
Publicado: (2007)

Transcriptome and Proteome Analysis in LUHMES Cells Overexpressing Alpha-Synuclein
por: Höllerhage, Matthias, et al.
Publicado: (2022)

mitoLUHMES: An Engineered Neuronal Cell Line for the Analysis of the Motility of Mitochondria
por: Stępkowski, Tomasz M., et al.
Publicado: (2016)

Antiparkinsonian Efficacy of Guanosine in Rodent Models of Movement Disorder
por: Massari, Caio M., et al.
Publicado: (2017)

Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease
por: Taguchi, Soutarou, et al.
Publicado: (2021)

Orthostatic Hypotension and Antiparkinsonian Drugs: A Systematic Review and Meta-analysis
por: Nimmons, Danielle, et al.
Publicado: (2021)

Striatal Neurons Partially Expressing a Dopaminergic Phenotype: Functional Significance and Regulation
por: Troshev, Dmitry, et al.
Publicado: (2022)

Protective efficacy of phosphodiesterase-1 inhibition against alpha-synuclein toxicity revealed by compound screening in LUHMES cells
por: Höllerhage, Matthias, et al.
Publicado: (2017)

Deciphering the Actions of Antiparkinsonian and Antipsychotic Drugs on cAMP/DARPP-32 Signaling
por: Bonito-Oliva, Alessandra, et al.
Publicado: (2011)

Impairment of Serotonergic Transmission by the Antiparkinsonian Drug L-DOPA: Mechanisms and Clinical Implications
por: Miguelez, Cristina, et al.
Publicado: (2017)

Predictive Factors of Antiparkinsonian Drug Reduction after Subthalamic Stimulation for Parkinson’s Disease
por: SAMURA, Kazuhiro, et al.
Publicado: (2019)

The Antiparkinsonian and Antidyskinetic Mechanisms of Mucuna pruriens in the MPTP-Treated Nonhuman Primate
por: Lieu, Christopher A., et al.
Publicado: (2012)

Antiparkinsonian Agents in Investigational Polymeric Micro- and Nano-Systems
por: Paccione, Nicola, et al.
Publicado: (2022)

A Monoiodotyrosine Challenge Test in a Parkinson’s Disease Model
por: Kim, A. R., et al.
Publicado: (2021)

Rapid preparation process of antiparkinsonian drug Mucuna pruriens silver nanoparticle by bioreduction and their characterization
por: Arulkumar, Subramanian, et al.
Publicado: (2010)

Trends in Antiparkinsonian Medication Use in New Zealand: 1995–2011
por: Pitcher, T. L., et al.
Publicado: (2014)

Parkinson's disease diffusion MRI is not affected by acute antiparkinsonian medication
por: Chung, Jae Woo, et al.
Publicado: (2017)

Antiparkinsonian effects of the "Radiprodil and Tozadenant" combination in MPTP-treated marmosets
por: Michel, Anne, et al.
Publicado: (2017)

A LUHMES 3D dopaminergic neuronal model for neurotoxicity testing allowing long-term exposure and cellular resilience analysis
por: Smirnova, L., et al.
Publicado: (2015)

Antiparkinsonian medication masks motor signal progression in de novo patients()
por: Brzezicki, Maksymilian A., et al.
Publicado: (2023)

Motor Improvement-Related Regional Cerebral Blood Flow Changes in Parkinson's Disease in Response to Antiparkinsonian Drugs
por: Taguchi, Soutarou, et al.
Publicado: (2019)

Isolation of living dopaminergic neurons labeled with a fluorescent ligand of the dopamine transporter from mouse substantia nigra as a new tool for basic and applied research
por: Troshev, Dmitry, et al.
Publicado: (2022)

Refined high-content imaging-based phenotypic drug screening in zebrafish xenografts
por: Sturtzel, C., et al.
Publicado: (2023)

Time until modification of antiparkinsonian therapy in a group of patients from Colombia
por: Valencia-Vásquez, Aníbal, et al.
Publicado: (2023)

The Alteration of Nasopharyngeal and Oropharyngeal Microbiota in Children with MPP and Non-MPP
por: Lu, Zhiwei, et al.
Publicado: (2017)

Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease
por: Calamini, Barbara, et al.
Publicado: (2021)

Compensatory Processes in Striatal Neurons Expressing the Tyrosine Hydroxylase Gene in Transgenic Mice in a Model of Parkinson’s Disease
por: Troshev, Dmitry, et al.
Publicado: (2023)

1,5-Benzodiazepin-2(3H)-ones: In Vitro Evaluation as Antiparkinsonian Agents
por: Ortíz de Zárate, Ana, et al.
Publicado: (2021)

2013 MPP Workshop
por: Jonker, Michael
Publicado: (2014)

Multi-parameter Behavioral Phenotyping of the MPP+ Model of Parkinson’s Disease in Zebrafish
por: Christensen, Christian, et al.
Publicado: (2020)

c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
por: Zhou, Yu, et al.
Publicado: (2018)

Characteristics of the mitochondrial and cellular uptake of MPP(+), as probed by the fluorescent mimic, 4'I-MPP(+)
por: Mapa, Mapa S. T., et al.
Publicado: (2018)

A New Stereoselective Approach to the Substitution of Allyl Hydroxy Group in para-Mentha-1,2-diol in the Search for New Antiparkinsonian Agents
por: Podturkina, Alexandra V., et al.
Publicado: (2023)

Proceedings of the 2019 MPP Workshop
por: Strachinescu, Sabina-Ioana, et al.
Publicado: (2019)

The Periventricular Nucleus as a Brain Center Containing Dopaminergic Neurons and Neurons Expressing Individual Enzymes of Dopamine Synthesis
por: Ugrumov, Michael V., et al.
Publicado: (2022)

The Sphingolipid Asset Is Altered in the Nigrostriatal System of Mice Models of Parkinson’s Disease
por: Blokhin, Victor, et al.
Publicado: (2022)

IL-6-Mediated Upregulated miRNAs in Extracellular Vesicles Derived from Lund Human Mesencephalic (LUHMES) Cells: Effects on Astrocytes and Microglia
por: Nishi, Kento, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3sg2a2tvvng46k875bjh6llfgn